Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air, Inc. (NASDAQ: XAIR) announced positive results from its third pilot study of inhaled Nitric Oxide (NO) in treating bronchiolitis in infants. The study revealed that 150 ppm NO significantly improved time to discharge and reduced hospital stay compared to lower concentrations and controls. Conducted in Israel with 89 participants under 12 months, the trial reported no serious adverse events related to NO therapy. The CEO emphasized the importance of these findings for future studies, particularly in COVID-19 treatments.
Beyond Air, Inc. (NASDAQ: XAIR) announced a new common stock purchase agreement with Lincoln Park Capital Fund, LLC for up to $40 million. This agreement extends until May 2023 and replaces an old one set to expire in August 2021. The company can sell 325,000 shares at $8.58 each, a 10% premium to the recent average price. This capital aims to support the advancement of its LungFit™ programs amid macroeconomic uncertainty. The agreement allows Beyond Air to control timing and terms of future investments without extensive financial covenants.